Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men

Ellen Scheers, Laurent Leclercq, Jan de Jong, Nini Bode, Marc Bockx, Aline Laenen, Filip Cuyckens, Donna Skee, Joe Murphy, Juthamas Sukbuntherng and Geert Mannens
Drug Metabolism and Disposition February 2015, 43 (2) 289-297; DOI: https://doi.org/10.1124/dmd.114.060061
Ellen Scheers
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Leclercq
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan de Jong
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nini Bode
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Bockx
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aline Laenen
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Cuyckens
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna Skee
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Murphy
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juthamas Sukbuntherng
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geert Mannens
Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 43 no. 2 289-297
DOI 
https://doi.org/10.1124/dmd.114.060061
PubMed 
25488930

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received July 22, 2014
  • Accepted December 4, 2014
  • Published online December 31, 2014.

Article Versions

  • Earlier version (December 8, 2014 - 06:43).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ellen Scheers,
  2. Laurent Leclercq,
  3. Jan de Jong,
  4. Nini Bode,
  5. Marc Bockx,
  6. Aline Laenen,
  7. Filip Cuyckens,
  8. Donna Skee,
  9. Joe Murphy,
  10. Juthamas Sukbuntherng, and
  11. Geert Mannens
  1. Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, California (J.d.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, New Jersey (D.S., J.M.); and Pharmacyclics, Sunnyvale, California (J.S.)
  1. Address correspondence to:
    Geert Mannens, Senior Scientific Director & Fellow, Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Turnhoutseweg 30, B-2340 Beerse, Belgium. E-mail: gmannens{at}its.jnj.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: December 2014 to June 2022

AbstractFullPdf
Dec 20145366195
Jan 201584640150
Feb 20153103674
Mar 20151873875
Apr 20151352436
May 2015982248
Jun 2015104815
Jul 2015791125
Aug 2015761434
Sep 2015761929
Oct 2015831964
Nov 2015732324
Dec 2015621730
Jan 2016525452
Feb 2016564766
Mar 2016557380
Apr 2016576654
May 2016626050
Jun 2016525455
Jul 2016424452
Aug 2016575861
Sep 2016243643
Oct 2016207451
Nov 2016139373
Dec 20161210364
Jan 201776734
Feb 2017910854
Mar 20171111878
Apr 2017149099
May 2017227376
Jun 2017129999
Jul 2017115551
Aug 2017207655
Sep 2017158783
Oct 2017237478
Nov 2017109967
Dec 201799548
Jan 20181111354
Feb 20181310759
Mar 20181113070
Apr 2018715771
May 20181011055
Jun 20181312366
Jul 201889560
Aug 201868855
Sep 201856532
Oct 2018139569
Nov 20181010576
Dec 201898347
Jan 2019159971
Feb 20191010165
Mar 201948465
Apr 20191315866
May 2019914885
Jun 2019109948
Jul 20191918071
Aug 20192312162
Sep 20195813849
Oct 20192512244
Nov 20191211975
Dec 2019107058
Jan 2020159769
Feb 2020510662
Mar 2020228658
Apr 2020714065
May 202059361
Jun 2020147876
Jul 20202610438
Aug 2020137359
Sep 2020126337
Oct 202096851
Nov 202097443
Dec 2020106457
Jan 20212092228
Feb 20211192530
Mar 20211301821
Apr 20211272227
May 20211201131
Jun 2021861923
Jul 20211181526
Aug 20211061321
Sep 20211091431
Oct 20211253028
Nov 20211801426
Dec 2021131925
Jan 2022751825
Feb 20221471523
Mar 2022951327
Apr 2022164824
May 20221161123
Jun 202283915

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (2)
Drug Metabolism and Disposition
Vol. 43, Issue 2
1 Feb 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Absorption, Metabolism, and Excretion of Ibrutinib

Ellen Scheers, Laurent Leclercq, Jan de Jong, Nini Bode, Marc Bockx, Aline Laenen, Filip Cuyckens, Donna Skee, Joe Murphy, Juthamas Sukbuntherng and Geert Mannens
Drug Metabolism and Disposition February 1, 2015, 43 (2) 289-297; DOI: https://doi.org/10.1124/dmd.114.060061

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Absorption, Metabolism, and Excretion of Ibrutinib

Ellen Scheers, Laurent Leclercq, Jan de Jong, Nini Bode, Marc Bockx, Aline Laenen, Filip Cuyckens, Donna Skee, Joe Murphy, Juthamas Sukbuntherng and Geert Mannens
Drug Metabolism and Disposition February 1, 2015, 43 (2) 289-297; DOI: https://doi.org/10.1124/dmd.114.060061
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TMDD Affects PK of IL-10 Fc-Fusion Proteins
  • In Vitro Models to Study P-gp-Mediated Intestinal DDIs
  • Covalent Inactivation of CYP3A by Futibatinib
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics